
George Lundberg, MD Editor in Chief at Cancer Commons
-
July 28, 2021
2021 ASCO Annual Meeting Bookmark
George Lundberg, MDResearchers at the 2021 annual meeting of the American Society of Clinical Oncology (ASCO) reported substantial advances in treatment for advanced esophageal, castration-resistant prostate, and metastatic nasopharyngeal cancers.
.
-
July 28, 2021
ARIEL4 Trial Confirms PFS Benefit of Rucaparib in BRCA+ Relapsed Ovarian Cancer Bookmark
George Lundberg, MDAs reported by Cancer Network, new results from a phase 3 clinical trial testing the drug rucaparib (Rubraca), which has already been approved by the U.S. Food and Drug Administration, show that it prolongs progression-free survival in some patients with advanced ovarian cancer.
.
-
July 28, 2021
FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy Bookmark
George Lundberg, MDOn May 28, 2021, the U.S. Food and Drug Administration granted Accelerated Approval for Lumakras (sotorasib), the first targeted therapy for cancer with a mutation in the KRAS gene.
.
-
July 28, 2021
Advances in Colorectal Cancer Research Bookmark
George Lundberg, MDThis outline from the National Cancer Institute covers recent research on colorectal cancer.
.
-
May 30, 2021
Cancer Support for LGBTQIA Patients Is Missing Bookmark
George Lundberg, MDThis piece from ASCO Connection outlines the need for and a path to improvement in cancer care for LGBTQIA patients.
.
-
May 4, 2021
Hepatocellular Carcinoma (HCC)—An Overview Bookmark
George Lundberg, MDOverview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:
This 2020 encyclopedic approach to all of the many diagnostic and therapeutic options available for primary hepatocellular carcinoma leaves no stone unturned. (Free registration required, written with a physician audience in mind.)
.
-
April 12, 2021
Sydney Researchers Identify/Advance Potential Revolutionary New Drug Treatment for Fatal Childhood Cancer Bookmark
George Lundberg, MDA press release from the Children’s Cancer Institute outlines hopeful results from experiments performed in mice and 3-D computer models that investigated a new treatment for the rare childhood brain tumor diffuse intrinsic pontine glioma (DIPG). The treatment consists of a combination of the drugs difluoromethylornithine (DFMO) and AMXT 1501. This combo is already being tested in clinical trials in adults with cancer, and will soon be tested in children with DIPG.
.
-
April 12, 2021
Chemo for Glioblastoma May Work Better in Morning Than Evening Bookmark
George Lundberg, MDA press release from ScienceDaily outlines results from a small study of patients receiving a standard, FDA-approved treatment (temozolomide) for glioblastoma. The results suggest that some patients may survive a few months longer, all because of time of day for administering the drug.
.
-
April 12, 2021
FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma Bookmark
George Lundberg, MDThe U.S. Food and Drug Administration (FDA) has approved a cell-based gene therapy known as lisocabtagene maraleucel (brand name Breyanzi) for relapsed or refractory large B-cell lymphoma.
.
-
April 12, 2021
Nivolumab: First Adjuvant Immunotherapy to Show Survival Benefit in High-Risk Muscle-Invasive Urothelial Cancer Bookmark
George Lundberg, MDThe ASCO Post reports new results from a clinical trial in which the drug nivolumab (Opdivo) nearly doubled progression-free survival compared to a placebo drug for people with muscle-invasive bladder cancer.
.